LFG
KYTX icon

Larson Financial Group’s Kyverna Therapeutics KYTX Stock Holding History

Larson Financial Group’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$356 Hold
40
– – ﹤0.01% 3548
2026
Q1 		$345 Buy
+40
New +$333 ﹤0.01% 3384

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.32B AUM 1.62% 1-Year Est. Return

Larson Financial Group's KYTX Position: Q2 2026 in Review

Larson Financial Group held its Kyverna Therapeutics (KYTX) position steady in Q2 2026 at 40 shares worth $356. The position accounts for ﹤0.01% of the portfolio, ranked #3548.

Larson Financial Group first reported a position in KYTX in Q1 2026 and has held it in 2 quarters since. 120 funds tracked by Wall St. Rank hold KYTX as of Q2 2026.

  • Larson Financial Group held 40 shares of Kyverna Therapeutics worth $356 as of Q2 2026.
  • Larson Financial Group left its Kyverna Therapeutics share count unchanged in Q2 2026.
  • Kyverna Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #3548 holding.
  • Larson Financial Group first reported a position in Kyverna Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 120 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.